Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2017

01-09-2017

Current evidence on vitamin D deficiency and kidney transplant: What’s new?

Authors: Gerardo Sarno, Riccardo Nappi, Barbara Altieri, Giacomo Tirabassi, Emanuele Muscogiuri, Gianmaria Salvio, Stavroula A. Paschou, Aristide Ferrara, Enrico Russo, Daniela Vicedomini, Cerbone Vincenzo, Andromachi Vryonidou, Silvia Della Casa, Giancarlo Balercia, Francesco Orio, Paride De Rosa

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2017

Login to get access

Abstract

Kidney transplant is the treatment of choice for end-stage chronic kidney disease. Kidneys generate 1,25-dihydroxyvitamin D (calcitriol) from 25-hydroxyvitamin D (calcidiol) for circulation in the blood to regulate calcium levels. Transplant patients with low calcidiol levels have an increased risk of metabolic and endocrine problems, cardiovascular disease, type 2 diabetes mellitus, poor graft survival, bone disorders, cancer, and mortality rate. The recommended calcidiol level after transplant is at least 30 ng/mL (75 nmol/L), which could require 1000–3000 IU/d vitamin D3 to achieve. Vitamin D3 supplementation studies have found improved endothelial function and acute rejection episodes. However, since kidney function may still be impaired, raising calcidiol levels may not lead to normal calcitriol levels. Thus, supplementation with calcitriol or an analog, alfacalcidiol, is often employed. Some beneficial effects found include possible improved bone health and reduced risk of chronic allograft nephropathy and cancer.
Literature
1.
Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–30.PubMedCrossRef
2.
Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, Klarenbach S, Gill J. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11:2093–109.PubMedCrossRef
3.
Weiner DE, Carpenter MA, Levey AS, Ivanova A, Cole EH, Hunsicker L, Kasiske BL, Kim SJ, Kusek JW, Bostom AG. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant. 2012;12:2437–45.PubMedPubMedCentralCrossRef
4.
Ojo AO, Morales JM, González-Molina M, Steffick DE, Luan FL, Merion RM, Ojo T, Moreso F, Arias M, Campistol JM, Hernandez D, Serón D. Scientific registry of transplant recipients and; spanish chronic allograft study group. comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant. 2013;28:213–20.PubMedCrossRef
5.
6.
7.
Ormsby RT, Findlay DM, Kogawa M, Anderson PH, Morris HA, Atkins GJ. Analysis of vitamin D metabolism gene expression in human bone: evidence for autocrine control of bone remodelling. J Steroid Biochem Mol Biol. 2014;144:110–3.PubMedCrossRef
8.
Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the reninangiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89–90:387–92.PubMedCrossRef
9.
Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int. 2008;73:163–71.PubMedCrossRef
10.
Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006;17:3382–93.PubMedCrossRef
11.
de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ. Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol. 2013;24:1863–71.PubMedPubMedCentralCrossRef
12.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97:1153–8.PubMedCrossRef
13.
Boudville NC, Hodsman AB. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant. 2006;21(9):2621–4.PubMedCrossRef
14.
Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-Hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab. 2006;91:526–9.PubMedCrossRef
15.
Sadlier DM, Magee CC. Prevalence of 25(OH) vitamin D (calcidiol) deficiency at time of renal transplantation: a prospective study. Clin Transpl. 2007;21:683–8.
16.
Keyzer CA, Riphagen IJ, Joosten MM, Navis G, Muller Kobold AC, Kema IP, Bakker SJ, de Borst MH. NIGRAM consortium. Associations of 25(OH) and 1,25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J Clin Endocrinol Metab. 2015;100:81–9.PubMedCrossRef
17.
Bienaimé F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H, Noël LH, Friedlander G, Elie C, Legendre C, Prié D. Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol. 2013;24:831–41.PubMedPubMedCentralCrossRef
18.
Barros X, Fuster D, Rodríguez N, Rodas L, Martínez-Osaba MJ, Campistol JM, Rubello D, Colletti PM, Campos F, Pons F, Torregrosa JV. Rapid calcitriol increase and persistent calcidiol insufficiency in the first 6 months after kidney transplantation. Nucl Med Commun. 2015;36:489–93.PubMed
19.
Dusso AS, Finch J, Brown A, Ritter C, Delmez J, Schreiner G, Slatopolsky E. Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab. 1991;72:157–64.PubMedCrossRef
20.
Brandenburg VM, Politt D, Ketteler M, Fassbender WJ, Heussen N, Westenfeld R, Freuding T, Floege J, Ittel TH. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation. 2004;77:1566–71.PubMedCrossRef
21.
Kodras K, Haas M. Effect of kidney transplantation on bone. Eur J Clin Investig. 2006;36(suppl 2):63–75.CrossRef
22.
Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis. 2000;36:160–6.PubMedCrossRef
23.
Alshayeb HM, Josephson MA, Sprague SM. CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis. 2013;61:310–25.PubMedCrossRef
24.
Marcén R, Jimenez S, Fernández-Rodriguez A, Galeano C, Villafruela JJ, Gomis A, Teruel JL, Quereda C. Are low levels of 25-hydroxyvitamin D a risk factor for cardiovascular diseases or malignancies in renal transplantation? Nephrol Dial Transplant. 2012;27(suppl 4):iv47–52.PubMedCrossRef
25.
Le Fur A, Fournier MC, Gillaizeau F, Masson D, Giral M, Cariou B, Cantarovich D, Dantal J. Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation. Transpl Int. 2016;29(2):207–15.PubMedCrossRef
26.
Courbebaisse M, Xu-Dubois YC, Thervet E, Prié D, Zuber J, Kreis H, Legendre C, Rondeau E, Pallet N. Cholecalciferol supplementation does not protect against renal allograft structural and functional deterioration: a retrospective study. Transplantation. 2011;91:207–12.PubMedCrossRef
27.
Courbebaisse M, Alberti C, Colas S, Prié D, Souberbielle JC, Treluyer JM, Thervet E. Vitamin D supplementation in renal transplant recipients (VITALE): a prospective, multicentre, double-blind, randomized trial of vitamin D estimating the benefit and safety of vitamin D3 treatment at a dose of 100,000 UI compared with a dose of 12,000 UI in renal transplant recipients: study protocol for a double-blind, randomized, controlled trial. Trials. 2014;15:430.PubMedPubMedCentralCrossRef
28.
Thiem U, Heinze G, Segel R, et al. VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome. Trials. 2009;10:36.PubMedPubMedCentralCrossRef
29.
Thiem U, Heinze G, Segel R, Perkmann T, Kainberger F, Mühlbacher F, Hörl W, Borchhardt K. Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation. 2013;95:e49–52.CrossRef
30.
Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol. 2015;26:1205–14.PubMedCrossRef
31.
Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, Heilman RL, Mazur MJ, Hamawi K, Larson TS, Kumar R. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant. 2013;13:1576–85.PubMedCrossRef
32.
Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation. 2005;79:108–15.PubMedCrossRef
33.
Sahin G, Yasar NS, Sirmagul B, Bal C, Yalcin AU. The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study. Ren Fail. 2008;30:992–9.PubMedCrossRef
34.
Courbebaisse M, Thervet E, Souberbielle JC, Zuber J, Eladari D, Martinez F, Mamzer-Bruneel MF, Urena P, Legendre C, Friedlander G, Prié D. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int. 2009;75:646–51.PubMedCrossRef
35.
Steiner RW, Ziegler M, Halasz NA, Catherwood BD, Manolagas S, Deftos LJ. Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1–25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation. 1993;56:843–6.PubMedCrossRef
36.
Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis. 2000;35:227–36.PubMedCrossRef
37.
Torres A, García S, Gómez A, González A, Barrios Y, Concepción MT, Hernández D, García JJ, Checa MD, Lorenzo V, Salido E. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int. 2004;65:705–12.PubMedCrossRef
38.
Stavroulopoulos A, Cassidy MJ, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant. 2007;7(11):2546–52.PubMedCrossRef
39.
Tripathi SS, Gibney EM, Gehr TW, King AL, Beckman MJ. High prevalence of vitamin D deficiency in African American kidney transplant recipients. Transplantation. 2008;85(5):767–70.PubMedCrossRef
40.
Ewers B, Gasbjerg A, Moelgaard C, Frederiksen AM, Marckmann P. Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr. 2008;87(2):431–7.PubMed
41.
Bienaime F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H, et al. Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol. 2013;24(5):831–41.PubMedPubMedCentralCrossRef
42.
Keyzer CA, Lambers-Heerspink HJ, Joosten MM, Deetman PE, Gansevoort RT, Navis G, et al. Plasma vitamin D level and change in albuminuria and eGFR according to sodium intake. Clin J Am Soc Nephrol. 2015;10(12):2119–27.PubMedPubMedCentralCrossRef
43.
Rizvi SM, Veierod MB, Thorsby PM, Helsing P. Vitamin D in Norwegian renal transplant recipients: a longitudinal study with repeated measurements in winter and summer. Eur J Dermatol. 2015;25(3):234–9.PubMed
44.
Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009;75(1):88–95.PubMedCrossRef
45.
Hullett DA, Laeseke PF, Malin G, Nessel R, Sollinger HW, Becker BN. Prevention of chronic allograft nephropathy with vitamin D. Transpl Int. 2005;18(10):1175–86.PubMedCrossRef
46.
Sarno G, Daniele G, Tirabassi G, Chavez AO, Ojo OO, Orio F, et al. The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes. Endocrine. 2015;50(3):568–74.PubMedCrossRef
47.
Ducloux D, Courivaud C, Bamoulid J, Kazory A, Dumoulin G, Chalopin JM. Pretransplant serum vitamin D levels and risk of cancer after renal transplantation. Transplantation. 2008;85(12):1755–9.PubMedCrossRef
48.
Sukumaran Nair S, Lenihan CR, Montez-Rath ME, Lowenberg DW, Chertow GM, Winkelmayer WC. Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States. Am J Transplant. 2014;14(4):943–51.PubMedPubMedCentralCrossRef
49.
Bouquegneau A, Salam S, Delanaye P, Eastell R, Khwaja A. Bone disease after kidney transplantation. Clin J Am Soc Nephrol. 2016;11(7):1282–96.PubMedPubMedCentral
50.
Malluche HH, Monier-Faugere MC, Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol. 2010;6(1):32–40.PubMedCrossRef
51.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.PubMedCrossRef
52.
53.
54.
Dusso A, Gonzalez EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab. 2011;25(4):647–55.PubMedCrossRef
55.
Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999;55(3):1019–27.PubMedCrossRef
56.
Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315–21.PubMedCrossRef
57.
Abdelbaqi-Salhab M, Shalhub S, Morgan MB. A current review of the cutaneous manifestations of renal disease. J Cutan Pathol. 2003;30(9):527–38.PubMedCrossRef
58.
Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D Insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24(5):503–10.PubMedCrossRef
59.
Mawer EB, Taylor CM, Backhouse J, Lumb GA, Stanbury SW. Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency. Lancet. 1973;1(7804):626–8.PubMedCrossRef
60.
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205–15.PubMedCrossRef
61.
Hsu CH, Vanholder R, Patel S, De Smet RR, Sandra P, Ringoir SM. Subfractions in uremic plasma ultrafiltrate inhibit calcitriol metabolism. Kidney Int. 1991;40(5):868–73.PubMedCrossRef
62.
Kawashima H, Kraut JA, Kurokawa K. Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action. J Clin Invest. 1982;70(1):135–40.PubMedPubMedCentralCrossRef
63.
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–35.PubMedCrossRef
64.
Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92(3):1436–43.PubMedPubMedCentralCrossRef
65.
Wolpaw T, Deal CL, Fleming-Brooks S, Bartucci MR, Schulak JA, Hricik DE. Factors influencing vertebral bone density after renal transplantation. Transplantation. 1994;58(11):1186–9.PubMedCrossRef
66.
Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Schollmeyer PJ. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation. 1995;59(7):982–6.PubMedCrossRef
67.
Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol. 2000;11(6):1093–9.PubMed
68.
Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991;325(8):544–50.PubMedCrossRef
69.
Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73–81.PubMedCrossRef
70.
71.
Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and nutrition examination survey (NHANES): 2001-2006. J Clin Endocrinol Metab. 2011;96(12):3838–45.PubMedPubMedCentralCrossRef
72.
Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005;115(1):177–86.PubMedPubMedCentralCrossRef
73.
Vlachopanos G, Bridson JM, Sharma A, Halawa A. Corticosteroid minimization in renal transplantation: careful patient selection enables feasibility. World J Transplant. 2016;6(4):759–66.PubMedPubMedCentralCrossRef
74.
Lee CT, Ng HY, Lien YH, Lai LW, Wu MS, Lin CR, et al. Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol. 2011;34(1):87–94.PubMedCrossRef
75.
Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant. 2007;7(5):1193–200.PubMedCrossRef
76.
Lou I, Foley D, Odorico SK, Leverson G, Schneider DF, Sippel R, et al. How well does renal transplantation cure hyperparathyroidism? Ann Surg. 2015;262(4):653–9.PubMedPubMedCentralCrossRef
77.
Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant. 1998;13(Suppl 3):94–7.PubMedCrossRef
78.
Akaberi S, Lindergard B, Simonsen O, Nyberg G. Impact of parathyroid hormone on bone density in long-term renal transplant patients with good graft function. Transplantation. 2006;82(6):749–52.PubMedCrossRef
79.
Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int. 1998;54(5):1704–13.PubMedCrossRef
80.
Giannini S, D'Angelo A, Nobile M, Carraro G, Rigotti P, Silva-Netto F, et al. The effects of vitamin D receptor polymorphism on secondary hyperparathyroidism and bone density after renal transplantation. J Bone Miner Res. 2002;17(10):1768–73.PubMedCrossRef
81.
Marcen R, Ponte B, Rodriguez-Mendiola N, Fernandez Rodriguez A, Galeano C, Villafruela JJ, et al. Secondary hyperparathyroidism after kidney transplantation: a cross-sectional study. Transplant Proc. 2009;41(6):2391–3.PubMedCrossRef
82.
Giannini S, Sella S, Silva Netto F, Cattelan C, Dalle Carbonare L, Lazzarin R, et al. Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: role of calcium-sensing receptor polymorphisms and vitamin D deficiency. J Bone Miner Res. 2010;25(4):841–8.PubMed
83.
Reinhardt W, Bartelworth H, Jockenhovel F, Schmidt-Gayk H, Witzke O, Wagner K, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant. 1998;13(2):436–42.PubMedCrossRef
84.
Lee HH, Kim AJ, Ro H, Jung JY, Chang JH, Chung W, et al. Sequential changes of vitamin D level and parathyroid hormone after kidney transplantation. Transplant Proc. 2016;48(3):897–9.PubMedCrossRef
85.
Sezer S, Yavuz D, Canoz MB, Ozdemir FN, Haberal M. Vitamin D status, bone mineral density, and inflammation in kidney transplantation patients. Transplant Proc. 2009;41(7):2823–5.PubMedCrossRef
86.
Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992–2000.PubMedPubMedCentralCrossRef
87.
Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3–24.PubMed
88.
Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis. 2004;43(6):953–65.PubMedCrossRef
89.
Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol. 2011;8(1):34–42.PubMedCrossRef
90.
Burroughs TE, Swindle J, Takemoto S, Lentine KL, Machnicki G, Irish WD, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation. 2007;83(8):1027–34.PubMedCrossRef
91.
Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care. 2012;35(1):181–8.PubMedCrossRef
92.
Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69(3):588–95.PubMedCrossRef
93.
Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62(4):1440–6.PubMedCrossRef
94.
Gosmanov AR, Dagogo-Jack S. Predicting, managing and preventing new-onset diabetes after transplantation. Minerva Endocrinol. 2012;37(3):233–46.PubMed
95.
Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92(6):2017–29.PubMedPubMedCentralCrossRef
96.
Altieri B, Grant WB, Casa SD, Orio F, Pontecorvi A, Colao A et al. Vitamin D and pancreas: the role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. Crit Rev Food Sci Nutr. 2016. doi:10.​1080/​10408398.​2015.​1136922.
97.
Tai K, Need AG, Horowitz M, Chapman IM. Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition. 2008;24(3):279–85.PubMedCrossRef
98.
Muscogiuri G, Altieri B, Annweiler C, Balercia G, Pal HB, Boucher BJ, et al. Vitamin D and chronic diseases: the current state of the art. Arch Toxicol. 2017;91(1):97–107.PubMedCrossRef
99.
National Kidney Fundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201.
100.
Jiménez Álvaro S, Marcén R, Villacorta J, Fernández-Rodríguez A, Galeano C, Villafruela JJ, Teruel JL, Burgos FJ, Quereda C. Cholecalciferol supplements improve vitamin D deficiency in renal transplant recipients. Transplant Proc. 2010;42:2921–3.PubMedCrossRef
101.
El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005;67:2039–45.PubMedCrossRef
102.
Sikgenc MM, Paydas S, Balal M, Demir E, Kurt C, Sertdemir Y, Binokay F, Erken U. Bone disease in renal transplantation and pleotropic effects of vitamin D therapy. Transplant Proc. 2010;42:2518–26.PubMedCrossRef
103.
Mainra R, Elder GJ. Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol. 2010;5:117–24.PubMedPubMedCentralCrossRef
104.
Tałałaj M, Gradowska L, Marcinowska-Suchowierska E, et al. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant Proc. 1996;28:3485–7.PubMed
105.
Berczi C, Asztalos L, Kincses Z, Balogh A, Löcsey L, Balázs G, Lukács G. Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation. Osteoporos Int. 2003;14:412–7.PubMedCrossRef
106.
De Sévaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol. 2002;13:1608–14.PubMedCrossRef
107.
Uğur A, Güvener N, Işiklar I, Karakayali H, Erdal R. Efficiency of preventive treatment for osteoporosis after renal transplantation. Transplant Proc. 2000;32:556–7.PubMedCrossRef
108.
Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation. 2003;76:1498–502.PubMedCrossRef
109.
Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, Kim KR, Lee HC, Huh K, Lim SK. Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc. 2000;32:1876.PubMedCrossRef
110.
Atis O, Keles M, Cankaya E, Dogan H, Aksoy H, Akcay F. Vitamin D treatment effect on serum endocan and high-sensitivity C-Reactive protein levels in renal transplant patients. Prog Transplant. 2016. doi:10.​1177/​1526924816664086​.
111.
Ahmadpoor P, Ilkhanizadeh B, Ghasemmahdi L, et al. Effect of active vitamin D on expression of Co-stimulatory molecules and HLA-DR in renal transplant recipients. Exp Clin Transplant. 2009;2:99–103.
112.
Tanaci N, Karakose H, Guvener N, et al. Influence of 1,25-dihydroxyvitamin D3 as an Immunomodulator in renal transplant recipients: a retrospective cohort study. Transplant Proc. 2003;35:2885–7.PubMedCrossRef
113.
Pérez R, Calderón J, Carracedo J. Calcitriol induces apoptosis of incubated lymphocyte T cells from patients with acute renal graft rejection. Transplant Proc. 1999;31:2311–3.PubMedCrossRef
114.
Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest. 1987;79:1659–64.PubMedPubMedCentralCrossRef
115.
Sezer S, Uyar M, Arat Z, Ozdemir FN, Haberal M. Potential effects of 1,25-dihydroxyvitamin D3 in renal transplant recipients. Transplant Proc. 2005;37:3109–11.PubMedCrossRef
116.
Obi Y, Ichimaru N, Hamano T, et al. Orally active vitamin d for potential chemoprevention of posttransplant malignancy. Cancer Prev Res. 2012;5:1229–35.CrossRef
117.
Penny H, Frame S, Dickinson F, Garrett G, Young AR, Sarkany R, Chitalia N, Hampson G, Goldsmith D. Determinants of vitamin D status in long-term renal transplant patients. Clin Transpl. 2012;26:E617–23.CrossRef
118.
Burkhalter F, Schaub S, Dickenmann M. Preserved circannual rhythm of vitamin D in kidney transplant patients. Swiss Med Wkly. 2012;142:w13672.PubMed
119.
Mazzaferro S, Pasquali M, Pugliese F, Citterio F, Gargiulo A, Rotondi S, Tartaglione L, Conte C, Pirrò G, Taggi F. Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: a role for FGF23. J Nephrol. 2012;25:1108–18.PubMedCrossRef
120.
Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Turker T, Unal HU, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Caglar K, Vural A, Mallamaci F, Zoccali C. Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol. 2013;37:126–34.PubMedCrossRef
121.
Beique LC, Kline GA, Dalton B, Duggan K, Yilmaz S. Predicting deficiency of vitamin D in renal transplant recipients in northern climates. Transplantation. 2013;95:1479–84.PubMedCrossRef
122.
Kulshrestha S, Ojo AO, Luan FL. Metabolic syndrome, vitamin D deficiency and hypoadiponectinemia among nondiabetic patients early after kidney transplantation. Am J Nephrol. 2013;37:399–404.PubMedCrossRef
123.
Obi Y, Hamano T, Ichimaru N, Tomida K, Matsui I, Fujii N, Okumi M, Kaimori JY, Yazawa K, Kokado Y, Nonomura N, Rakugi H, Takahara S, Isaka Y, Tsubakihara Y. Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study. J Clin Endocrinol Metab. 2014;99:527–35.PubMedCrossRef
124.
Lee JR, Dadhania D, August P, Lee JB, Suthanthiran M, Muthukumar T. Circulating levels of 25-hydroxyvitamin D and acute cellular rejection in kidney allograft recipients. Transplantation. 2014;98:292–9.PubMedPubMedCentralCrossRef
Metadata
Title
Current evidence on vitamin D deficiency and kidney transplant: What’s new?
Authors
Gerardo Sarno
Riccardo Nappi
Barbara Altieri
Giacomo Tirabassi
Emanuele Muscogiuri
Gianmaria Salvio
Stavroula A. Paschou
Aristide Ferrara
Enrico Russo
Daniela Vicedomini
Cerbone Vincenzo
Andromachi Vryonidou
Silvia Della Casa
Giancarlo Balercia
Francesco Orio
Paride De Rosa
Publication date
01-09-2017
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2017
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-017-9418-z

Other articles of this Issue 3/2017

Reviews in Endocrine and Metabolic Disorders 3/2017 Go to the issue

ReviewPaper

Vitamin D: Musculoskeletal health

ReviewPaper

Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept

ReviewPaper

The role of vitamin D in male fertility: A focus on the testis

ReviewPaper

Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications

ReviewPaper

Shedding new light on female fertility: The role of vitamin D

ReviewPaper

Adrenal disorders: Is there Any role for vitamin D?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits